# A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

> **NCT04860297** · PHASE3 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 234 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** mRNA-1273

## Key facts

- **NCT ID:** NCT04860297
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-16
- **Primary completion:** 2023-05-22
- **Final completion:** 2023-05-22
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2024-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04860297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04860297, "A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04860297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*